BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

30 related articles for article (PubMed ID: 38660841)

  • 1. Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes.
    Gao Y; Jin F; Zhang P; Zheng C; Zheng X; Xie J; Lu Y; Tong X; Du J; Zhang J; Wang Y
    Biomed Pharmacother; 2024 Jun; 175():116727. PubMed ID: 38733771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qiju Dihuang Pill protects the lens epithelial cells via alleviating cuproptosis in diabetic cataract.
    Yang J; Gao Y; Mao H; Kuang X; Tian F
    J Ethnopharmacol; 2024 Jun; 333():118444. PubMed ID: 38851473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GSH exhaustion via inhibition of xCT-GSH-GPX4 pathway synergistically enhanced DSF/Cu-induced cuproptosis in myelodysplastic syndromes.
    Li H; Li Y; Yu Y; Ren X; Yang C; Jin W; Li K; Zhou Y; Wu C; Shen Y; Hu W; Liu Y; Yu L; Tong X; Du J; Wang Y
    Free Radic Biol Med; 2024 Jun; 222():130-148. PubMed ID: 38866192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomimetic copper-doped polypyrrole nanoparticles induce glutamine metabolism inhibition to enhance breast cancer cuproptosis and immunotherapy.
    Zhang N; Ping W; Rao K; Zhang Z; Huang R; Zhu D; Li G; Ning S
    J Control Release; 2024 May; 371():204-215. PubMed ID: 38810704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Copper's dual role: unravelling the link between copper homeostasis, cuproptosis, and cardiovascular diseases.
    Parsanathan R
    Hypertens Res; 2024 May; 47(5):1440-1442. PubMed ID: 38467792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elesclomol: a copper ionophore targeting mitochondrial metabolism for cancer therapy.
    Zheng P; Zhou C; Lu L; Liu B; Ding Y
    J Exp Clin Cancer Res; 2022 Sep; 41(1):271. PubMed ID: 36089608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer.
    Yang W; Wang Y; Huang Y; Yu J; Wang T; Li C; Yang L; Zhang P; Shi L; Yin Y; Tao K; Li R
    Biomed Pharmacother; 2023 Mar; 159():114301. PubMed ID: 36706634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effects of
    Li Y; Shi LH; Xie X; Fan PK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Dec; 31(6):1599-1607. PubMed ID: 38071034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cuproptosis Induced by ROS Responsive Nanoparticles with Elesclomol and Copper Combined with αPD-L1 for Enhanced Cancer Immunotherapy.
    Guo B; Yang F; Zhang L; Zhao Q; Wang W; Yin L; Chen D; Wang M; Han S; Xiao H; Xing N
    Adv Mater; 2023 Jun; 35(22):e2212267. PubMed ID: 36916030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
    Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
    Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cuproptosis-Related Genes MTF1 and LIPT1 as Novel Prognostic Biomarker in Acute Myeloid Leukemia.
    Li Y; Kan X
    Biochem Genet; 2024 Apr; 62(2):1136-1159. PubMed ID: 37561332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Elesclomol-Cu Induces Cuproptosis in Human Acute Myeloid Leukemia Cells].
    Yu YH; Li HJ; Yang XY; Yu LY; Tong XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):389-394. PubMed ID: 38660841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug.
    Gao J; Wu X; Huang S; Zhao Z; He W; Song M
    Redox Biol; 2023 Nov; 67():102891. PubMed ID: 37734229
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.